-
Mashup Score: 0Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration - Leukemia - 2 year(s) ago
In AML patients, recurrent mutations were shown to persist in remission, however, only some have a prognostic value and persistent mutations might therefore reflect a re-established premalignant state or truly active disease causing relapse. We aimed to dissect the nature of co-mutations in NPM1 mutated AML where the detection of NPM1 transcripts allows highly specific and sensitive detection of…
Source: LeukemiaCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study - Leukemia - 2 year(s) ago
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and…
Source: LeukemiaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Most downloaded in November: COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study https://t.co/y9x3lySw4a #COVID19 #Chroniclymphocyticleukaemia #Epidemiology #Coronavirus https://t.co/9lXGpgQquk
-
-
Mashup Score: 11A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma - Leukemia - 2 year(s) ago
Osteonecrosis of the jaw (ONJ) is a reported complication of bisphosphonate use. The incidence ranges between 6 and 13% and seems to be higher in people treated with zoledronic acid (ZA) than with pamidronate. We retrospectively evaluated the incidences of ONJ and skeletal-related events (SRE) in 106 patients with multiple myeloma divided in two groups according to the schedule of administration…
Source: LeukemiaCategories: Hem/Oncs, Latest HeadlinesTweet-
ONJ-free survival : A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. https://t.co/VJMyrHSAAH #mmsm #USMRC #MedEd #MedTwitter #MYELOMA https://t.co/XyZqIBO6TO
-
-
Mashup Score: 2Nucleolin as activator of TCF7L2 in human hematopoietic stem/progenitor cells - Leukemia - 2 year(s) ago
Leukemia –
Nucleolin as activator of Source: LeukemiaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nucleolin as activator of TCF7L2 in human hematopoietic stem/progenitor cells Read for free: https://t.co/JsNMPTIWhA #Cellsignalling #Haematopoieticstemcells https://t.co/3hKVRsEeJI
-
-
Mashup Score: 2
Numerous targeted therapies have been developed for diffuse large B-cell lymphoma, but the results of late-stage clinical trials were mostly disappointing and have led to very few new regulatory approvals. Here, we use single and combinatorial drug response profiling to show that the combined inhibition of the anti-apoptotic protein Bcl-2 and of the tyrosine kinase BTK with the small molecules…
Source: LeukemiaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Inhibitors of Bcl-2 and Bruton’s tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models Read for free: https://t.co/StCa48Afwd #Bcelllymphoma #Preclinicalresearch #Translationalresearch https://t.co/qVF3bHi4Pa
-
-
Mashup Score: 0Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse - Leukemia - 2 year(s) ago
Achieving a complete response (CR) is associated with improved overall survival (OS) in multiple myeloma (MM), but data on duration of CR (DurCR) are limited. We evaluated 351 patients (2004–2016), achieving CR with first-line therapy. Patients with sustained DurCR ≥ 24 months (n = 177) had better OS; 150 vs. 81 months, p < 0.001. DurCR ≥ 24 months remained a significant predictor for OS (HR:...
Source: LeukemiaCategories: Hem/Oncs, Latest HeadlinesTweet-
@mwschoen @ManniMD1 @AaronGoodman33 @VincentRK This one covers a bit of this topic. "Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse". 2018 from @VincentRK @MorieGertz @myelomaMD #mmsm https://t.co/hkSqDB3a3F
-
-
Mashup Score: 0MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis - Leukemia - 2 year(s) ago
Erdheim–Chester disease (ECD) is characterized by excessive production and accumulation of histiocytes within multiple tissues and organs. ECD patients harbor recurrent mutations of genes associated with the RAS/RAF/MEK/ERK signaling pathway, particularly, the BRAFV600E mutation. Following our previous finding that miR-15a-5p is the most prominently downregulated microRNA in ECD patients compared…
Source: LeukemiaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis Read for free: https://t.co/D1ScKcubKE #Cellsignalling #Haematologicalcancer https://t.co/p9FbUBo2z7
-
-
Mashup Score: 10Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies - Leukemia - 2 year(s) ago
Leukemia –
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new… Source: LeukemiaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @SusanBal9: 1/ Our study evaluating outcomes of TCR MM out today in @leukemiajnl https://t.co/UzUAQ3IWFm
-
-
Mashup Score: 9Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies - Leukemia - 2 year(s) ago
Leukemia –
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new… Source: LeukemiaCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @SusanBal9: 1/ Our study evaluating outcomes of TCR MM out today in @leukemiajnl https://t.co/UzUAQ3IWFm
-
-
Mashup Score: 0Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies - Leukemia - 2 year(s) ago
Leukemia –
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new… Source: LeukemiaCategories: Hem/Oncs, Latest HeadlinesTweet-
1/ Our study evaluating outcomes of TCR MM out today in @leukemiajnl https://t.co/UzUAQ3IWFm
-
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration [Aug 10, 2021] Luca Vincenzo Cappelli et al. @LeukemiaJnl https://t.co/bffwCpB7H2 #AML #leusm #mdssm #camoldx #OpenAccess